285 related articles for article (PubMed ID: 28833722)
21. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
22. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
[TBL] [Abstract][Full Text] [Related]
23. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
24. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
25. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
26. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
27. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
28. Advanced melanoma in adults: Pembrolizumab as a treatment option.
Silvinato A; Bernardo WM; Floriano I
Rev Assoc Med Bras (1992); 2020 May; 66(2):100-107. PubMed ID: 32428140
[TBL] [Abstract][Full Text] [Related]
29. Diffuse Hepatic Infiltration by Metastatic Melanoma.
Velázquez HE; Castro-Alonso FJ; Bourlon C; Gabutti A; Gallegos C; Bourlon MT
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365754
[No Abstract] [Full Text] [Related]
30. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
[No Abstract] [Full Text] [Related]
31. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M; Mirkin V; Braester A; Harpaz N; Shevetz O; Shtreiter M; Greenberg S; Mordich O; Amram O; Binsky-Ehrenreich I; Marom A; Shachar I; Herishanu Y; Ruchlemer R; Berrebi A; Valinsky L; Shtalrid M; Shvidel L
Br J Haematol; 2018 Jul; 182(1):125-128. PubMed ID: 28466956
[No Abstract] [Full Text] [Related]
32. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
33. Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Simetić L; Blažičević K; Međugorac K; Golčić M; Herceg D
Anticancer Res; 2020 Apr; 40(4):2157-2163. PubMed ID: 32234909
[TBL] [Abstract][Full Text] [Related]
34. The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
Ladwa R; Atkinson V
Melanoma Res; 2017 Apr; 27(2):168-170. PubMed ID: 28099369
[TBL] [Abstract][Full Text] [Related]
35. A rapid response to pembrolizumab in a patient with metastatic melanoma.
Bayo Calero J; Aviñó Tarazona V
Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
[TBL] [Abstract][Full Text] [Related]
36. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
37. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
[TBL] [Abstract][Full Text] [Related]
38. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
39. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.
Cohen JV; Alomari AK; Vortmeyer AO; Jilaveanu LB; Goldberg SB; Mahajan A; Chiang VL; Kluger HM
Cancer Immunol Res; 2016 Mar; 4(3):179-82. PubMed ID: 26701266
[TBL] [Abstract][Full Text] [Related]
40. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.
Korman AM; Hastings JG; Byrd JC; Kaffenberger BH
JAMA Dermatol; 2017 Jan; 153(1):108-110. PubMed ID: 27892987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
